Seizure adequacy and safety of remimazolam in electroconvulsive therapy for patients with psychiatric disorders: a double-blind randomized crossover trial
Tianqi Shen, Xingxing Yin, Yongming Zhang, Feng Wang, Haipeng Wang, Xiufang Shi, Yanmiao Qiu, Jia Li, Xinhong Du · 2026
Read Seizure adequacy and safety of remimazolam in electroconvulsive therapy for patients with psychiatric disorders: a double-blind randomized crossover trial by Tianqi Shen, Xingxing Yin, Yongming Zhang, Feng Wang, Haipeng Wang, Xiufang Shi, Yanmiao Qiu, Jia Li, Xinhong Du (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13474910.txt.
Description
Tianqi Shen and eight colleagues compared in 2026 two anaesthetics for electroconvulsive therapy in patients with hard-to-treat mental disorders. In a double-blind trial, patients received remimazolam or propofol in turn for induction, with brain seizure length as the main outcome.
Remimazolam produced longer brain and muscle seizure durations and higher seizure energy measures than propofol. It also brought more post-seizure high blood pressure and fast heart rate, plus slower induction and recovery. The authors judge remimazolam good for seizure quality, while warning clinicians to watch post-seizure heart surges.
Catalog record
| CREATOR | Tianqi Shen, Xingxing Yin, Yongming Zhang, Feng Wang, Haipeng Wang, Xiufang Shi, Yanmiao Qiu, Jia Li, Xinhong Du |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |